BAT Malaysia Pins Hopes on Dunhill to Reverse Sales Decline in SA Countries

BAT by 2FIRSTS.ai
Feb.07.2024
BAT Malaysia Pins Hopes on Dunhill to Reverse Sales Decline in SA Countries
British American Tobacco's Malaysian subsidiary hopes that the Vuse e-cigarette will boost sales in Southeast Asia.

British American Tobacco Malaysia is hopeful that its brand "Dunhill" cigarettes will help reverse the decline in sales in Southeast Asian countries.

 

Nedal Louay Salem, the General Manager of British American Tobacco (Malaysia) Company, has stated that a rule reform introduced last year has enabled the company to start selling the Vuse brand of e-cigarettes in Malaysia. This has doubled the potential market size for the tobacco company locally, leading to significant confidence in the Vuse brand.

 

During an interview with Dow Jones Newswires, Salim expressed his ambition, stating, "Our objective is to establish Vuse as the e-cigarette equivalent of Dunhill in the cigarette industry. Our aim is to become Malaysia's leading vape brand.

 

He stated that these efforts have laid the foundation for an increase in sales. "In 2024, our sales will definitely be better than in the past.

 

As the manufacturer of one of Malaysia's most popular cigarette brands, Dunhill, British American Tobacco is facing formidable challenges in the country. The increasingly intense competition from unregulated vape products and illicit tobacco products has significantly eroded the market share of traditional cigarettes.

 

For most of the past decade, the company has experienced a continuous decline in profits, with its stock price falling by approximately 76% over the past five years. This year, the company's stock price has further dropped by 2.1%, leading BAT Malaysia's market value to fall below $550 million.

 

Analysts predict that during BAT Malaysia's financial report release on Tuesday evening, its sales for 2023 are expected to reach MYR 2.36 billion (approximately USD 496.8 million), which is lower than MYR 2.6 billion in 2022 and MYR 2.64 billion in 2021.

 

Salim highlighted that in the short term, the company's bottom line may continue to face pressure due to its investment in the "right mix of channels" to gain market share in the smoking accessories industry, following the launch of Vuse in Malaysia last August.

 

It is crucial for BAT to increase the sales of Vuse to the level of its competitor Dunhill cigarettes. According to their 2022 annual report, British American Tobacco's Malaysian branch, Dunhill, holds a 32% market share in the Malaysian tobacco market, dominating 62% of the country's high-end market.

 

Simultaneously, the company plans to continue improving its traditional products. Salim mentioned that consumption of the affordable Luckies cigarettes, introduced by BAT last year, has experienced rapid growth, while inflation risks are high at this time, particularly with impending subsidy cuts and tax increases.

 

Salim stated that BAT has a series of new product plans to be launched in the next nine months. He further added that the expansion into the e-cigarette sector supports the company's intent to not delist or go private, which was previously speculated by market analysts in the case of prolonged decline in the company's stock price.

 

"We are facing tremendous opportunities," he stated. "This is where the company's focus should lie, rather than privatization."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
Kumulus Vape, Europe’s first publicly listed vape company, reported a 7.8% year-on-year decline in first-half 2026 revenue. Amid changing conditions in France’s vape market, the company said channel diversification helped offset pressure, with physical store sales increasing 41.5% year on year. Listed on Euronext Access Paris in 2019 and later transferred to Euronext Growth Paris, Kumulus Vape is viewed as a representative company of Europe’s vape sector. Its performance highlights the industry’s shift from rapid expansion toward more operationally focused growth.
Jul.27
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
China Tobacco Regulator Deputy Head Visits Laos as Both Sides Strengthen Cooperation on Illegal Tobacco Trade
China Tobacco Regulator Deputy Head Visits Laos as Both Sides Strengthen Cooperation on Illegal Tobacco Trade
China’s official Xinhua News Agency reported that Liu Sanjiang, deputy head and Party group member of China’s tobacco regulator, led a delegation to Laos from July 31 to Aug. 2, 2026, for discussions with Lao authorities on combating cross-border illegal tobacco trade. The two sides discussed areas including law enforcement cooperation, information sharing and efforts to address tobacco-related illegal activities such as counterfeiting and smuggling. The visit highlights cooperation between Chinese and Lao authorities on illicit tobacco control.
News
Aug.05
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26